LLY
LLY
NYSE · Pharmaceuticals

Eli Lilly and Co.

S&P 500 Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks
$1,102.08
+3.51 (+0.32%)
As of Jun 22, 9:30 PM ET ·
Financial Highlights (FY 2026)
Revenue
68.26B
Net Income
21.61B
Gross Margin
83.0%
Profit Margin
31.7%
Rev Growth
+31.7%
D/E Ratio
1.60
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.0% 83.0% 56.4% 56.4%
Operating Margin 40.3% 36.3% 27.5% 24.1%
Profit Margin 31.7% 30.1% 18.8% 23.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 68.26B 51.83B 262.19B 288.72B
Gross Profit 56.68B 43.04B 147.80B 162.76B
Operating Income 27.54B 18.82B 72.23B 69.71B
Net Income 21.61B 14.77B 49.23B 68.90B
Gross Margin 83.0% 83.0% 56.4% 56.4%
Operating Margin 40.3% 36.3% 27.5% 24.1%
Profit Margin 31.7% 30.1% 18.8% 23.9%
Rev Growth +31.7% +31.7% +3.8% -0.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 318.47B 318.47B 59.02B 45.19B
Total Equity 198.82B 198.82B 657.24B 666.99B
D/E Ratio 1.60 1.60 0.09 0.07
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 29.63B 21.38B 80.48B 106.53B
Free Cash Flow — — 35.91B 45.81B